ClinicalTrials.gg
CompletedNCT05042362OASIS-1Updated Feb 12, 2026Results posted

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

A Phase 3 interventional study of Elinzanetant (BAY3427080) and Placebo in Vasomotor Symptoms Associated With Menopause and Hot Flashes, sponsored by Bayer. Completed at 99 sites in 8 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing elinzanetant in Hot Flashes — none open to participants now, 1 under way, 1 of them phase 3. elinzanetant · Hot Flashes.

Enrollment
4th of 13
396 · median 64
Started
2021
with 4 others
Phase 3
4 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
13 of 13
Bayer

Among the 13 studies testing elinzanetant in Hot Flashes, this one is the 4th largest by enrollment, is one of 5 that started in 2021, is one of 4 in phase 3, and was the 3rd registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 13 studies testing elinzanetant in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

About elinzanetant

elinzanetant: first FDA approval 2025 (LYNKUET), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing elinzanetant in Hot Flashes as a file.
02

Study summary

Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life.

The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people.

In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment.

The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks.

During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks.

During the study, the participants will:

  • record information about the participants' hot flashes in an electronic diary
  • answer questions about the participants' symptoms

The doctors will:

  • check the participants' health
  • take blood samples
  • ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.
03

Conditions studied

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Browse trials for

Keywords

  • Menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • , defined as:

    1. at least 12 months of spontaneous amenorrhea prior to signing of , or
    2. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    3. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels > 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or
    4. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent.
  • Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition.
  • Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit, and participant has recorded at least 50 moderate or severe HF (including night-time HF) over the last 7 days that the HFDD was completed (assessed at the Baseline Visit).

Exclusion criteria

Exclusion Criteria:

  • Any prior or ongoing history of arrhythmias, heart block and either determined through clinical history or on evaluation.
  • Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome.
  • Current or history (except complete remission for 5 years or more) of any (except basal and squamous cell skin tumors). Women receiving endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study.
  • Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if these women are medically cleared prior to study participation.
  • Untreated hyperthyroidism or hypothyroidism.

    • Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for > 6 months before signing of is acceptable.
    • Treated hypothyroidism with normal thyroid function test results during screening and a stable (for ≥ 3 months before signing of informed consent) dose of replacement therapy is acceptable.
  • Any unexplained uterine bleeding.
  • Clinically relevant abnormal findings on mammogram.
  • Abnormal liver parameters.
  • Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial during screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Elinzanetant (BAY3427080)

    Participants will receive 120 mg elinzanetant orally once daily for 26 weeks.

    Drug: Elinzanetant (BAY3427080)

  • Placebo comparator
    Placebo + elinzanetant

    Participants will receive matching placebo orally once daily for 12 weeks, followed by elinzanetant 120 mg for 14 weeks.

    Drug: Elinzanetant (BAY3427080) · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 4, Days 22-28 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

    Time frame: From baseline to Week 4

  2. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 12, Days 78-84 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

    Time frame: From baseline to Week 12

  3. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).

    In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing.

    Time frame: From baseline to Week 4

  4. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).

    In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

    Time frame: From baseline to Week 12

Secondary outcomes

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD).

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 1, Days 2-8 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

    Time frame: From baseline to Week 1

  2. Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time.

    The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 1 Days 2-8 were used instead of 1-7, because the intake started on Day 1 only before going to bed, for Week 4 Days 22-28 were used and for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment). These data were aggregated to a mean daily frequency as (total number of moderate to severe HF during that week) / (total number of available days with data during that week). In case data was not available for more than 2 days within a week, the value for that particular week was set to missing.

    Time frame: From baseline to Week 30

  3. Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12.

    In controversy of what you have been proposing above here you are just explaining the PROMIS SD SF 8b scores, not the secondary endpoint which is the change in the T-scores from BL to week 12 The PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) measures sleep disturbance over the past 7 days using 8 items assessing sleep quality, depth, restorative sleep, difficulty falling or staying asleep, and perceptions of sleep adequacy and satisfaction. Items use 5-point response options that vary by item (e.g., Not at all → Very much; Never → Always; Very poor → Very good). Item scores sum to a raw score of 8-40, which is converted to a T-score (mean 50, SD 10; range 28.9-76.5). Higher scores reflect greater sleep disturbance. PROMIS cut points classify T-scores of 55-59 as mild, 60-69 as moderate, and ≥70 as severe disturbance.

    Time frame: From baseline to Week 12

  4. Mean Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12.

    The MENQOL questionnaire was comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assessed four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicated if they had experienced the symptom (yes/no). If participants selected yes, participants rated how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score were calculated. Each score ranged from 1-8, higher scores indicated greater bother.

    Time frame: From baseline to Week 12

  5. Mean Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12.

    The BDI-II was a 21-item questionnaire assessed the intensity of depressive symptoms over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 mild depression, 20 - 28 indicating moderate and 29 - 63 severe depression (higher score = greater depression).

    Time frame: From baseline to Week 12

  6. Mean Change in BDI-II Total Score From Baseline to Week 26.

    The BDI-II was a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 mild depression, 20 - 28 indicating moderate and 29 - 63 severe depression (higher score = greater depression).

    Time frame: From baseline to Week 26

07

Results

Posted Feb 12, 2026

Participant flow

Study was conducted at 89 study centers in 8 countries, between 27-Aug-2021 (first participant first visit) and 27-Nov-2023 (last participant last visit).

Participant flow — Overall Study
MilestoneElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Started199197
Completed154155
Not completed4542
Withdrew: Adverse event79
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up74
Withdrew: Missing42
Withdrew: Withdrawal by subject59
Withdrew: Randomized by mistake12
Withdrew: Physician decision30
Withdrew: Other01
Withdrew: Non-compliance with study drug23
Withdrew: Incompleted treatment; finished follow-up1610

Outcome measures

PrimaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 4, Days 22-28 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

Time frame:
From baseline to Week 4
Reported as:
Mean · Hot Flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).
Hot Flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline13.38 ± 6.5714.26 ± 13.94
Week 4: Change from baseline-7.48 ± 5.80-4.37 ± 6.73
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · Mixed model repeated measures (MMRM) · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -3.29 · 95% CI -4.47 to -2.10
PrimaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 12, Days 78-84 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

Time frame:
From baseline to Week 12
Reported as:
Mean · Hot Flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).
Hot Flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline13.38 ± 6.5714.26 ± 13.94
Week 12: Change from baseline-8.74 ± 6.70-5.53 ± 10.16
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (one-sided) · Difference in ls-means: -3.22 · 95% CI -4.81 to -1.63
PrimaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).

In the HFDD, hot flash (HF) severity is scored as 1=mild, 2=moderate, and 3=severe; a decrease indicates improvement. The diary records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate are "heat with sweating but able to continue activity"; severe are "heat with sweating that stops activity." Baseline mean daily severity is calculated as: (2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs).(2 × moderate HFs + 3 × severe HFs) ÷ (total moderate + severe HFs).(2×moderateHFs+3×severeHFs)÷(totalmoderate+severeHFs). If none occur, severity=0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging the mean daily severity for that week. If more than 2 days are missing, the weekly value is set to missing.

Time frame:
From baseline to Week 4
Reported as:
Mean · Units on a scale
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).
Units on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline2.56 ± 0.222.53 ± 0.23
Week 4: Change from baseline-0.73 ± 0.64-0.39 ± 0.43
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -0.33 · 95% CI -0.44 to -0.23
PrimaryMean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).

In the HFDD, hot flash (HF) severity is categorized as 1=mild, 2=moderate, 3=severe; thus, a decrease indicates improvement. The HFDD records the number of mild, moderate, and severe HFs during day and night. Mild HFs are a "sensation of heat without sweating"; moderate involve "heat with sweating but able to continue activity"; severe involve "heat with sweating that stops activity." Mean daily severity at baseline is calculated as: (2 × moderate HFs) + (3 × severe HFs)\\\] ÷ (total moderate + severe HFs). If none occur, severity is set to 0. Weekly severity during treatment is based on available days (Week 4: Days 22-28; Week 12: Days 78-84; Day 1=start of treatment), averaging mean daily severity across that week. If more than 2 days are missing, the week is set to missing.

Time frame:
From baseline to Week 12
Reported as:
Mean · Units on a scale
Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).
Units on a scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline2.56 ± 0.222.53 ± 0.23
Week 12: Change from baseline-0.95 ± 0.78-0.55 ± 0.60
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -0.40 · 95% CI -0.54 to -0.25
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD).

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically for Week 1, Days 2-8 were used (Day 1 corresponds to start of treatment). Mean daily frequency is calculated as total number of moderate to severe HF during that week divided by the total number of available days with data during that week

Time frame:
From baseline to Week 1
Reported as:
Mean · Hot Flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 1 (Assessed by HFDD).
Hot Flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline13.38 ± 6.5714.26 ± 13.94
Week 1: Change from baseline-5.00 ± 5.05-2.72 ± 4.99
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -2.45 · 95% CI -3.36 to -1.55
SecondaryMean Change in Frequency of Moderate to Severe HF From Baseline Over Time.

The frequency of moderate to severe HF for each week during the treatment period was calculated using the available data during that particular week. Specifically, for Week 1 Days 2-8 were used instead of 1-7, because the intake started on Day 1 only before going to bed, for Week 4 Days 22-28 were used and for Week 12 Days 78-84 were used (Day 1 corresponds to start of treatment). These data were aggregated to a mean daily frequency as (total number of moderate to severe HF during that week) / (total number of available days with data during that week). In case data was not available for more than 2 days within a week, the value for that particular week was set to missing.

Time frame:
From baseline to Week 30
Reported as:
Mean · Hot Flashes per day
Mean Change in Frequency of Moderate to Severe HF From Baseline Over Time.
Hot Flashes per dayElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline13.38 ± 6.5714.26 ± 13.94
Week 1: Change from baseline-5.00 ± 5.05-2.72 ± 4.99
Week 4: Change from baseline-7.48 ± 5.8-4.37 ± 6.73
Week 8: Change from baseline-8.42 ± 6.5-5.24 ± 8.08
Week 12: Change from baseline-8.74 ± 6.7-5.53 ± 10.16
Week 16: Change from baseline-9.19 ± 6.21-8.08 ± 8.87
Week 20: Change from baseline-9.87 ± 6.40-8.88 ± 8.30
Week 26: Change from baseline-10.11 ± 6.41-10.10 ± 8.75
Week 30: Change from baseline-6.70 ± 5.99-6.15 ± 10.52
SecondaryMean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12.

In controversy of what you have been proposing above here you are just explaining the PROMIS SD SF 8b scores, not the secondary endpoint which is the change in the T-scores from BL to week 12 The PROMIS Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) measures sleep disturbance over the past 7 days using 8 items assessing sleep quality, depth, restorative sleep, difficulty falling or staying asleep, and perceptions of sleep adequacy and satisfaction. Items use 5-point response options that vary by item (e.g., Not at all → Very much; Never → Always; Very poor → Very good). Item scores sum to a raw score of 8-40, which is converted to a T-score (mean 50, SD 10; range 28.9-76.5). Higher scores reflect greater sleep disturbance. PROMIS cut points classify T-scores of 55-59 as mild, 60-69 as moderate, and ≥70 as severe disturbance.

Time frame:
From baseline to Week 12
Reported as:
Mean · T-score
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline to Week 12.
T-scoreElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline61.0 ± 7.760.2 ± 7.2
Week 12: Change from baseline-10.8 ± 9.6-5.0 ± 6.9
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -5.58 · 95% CI -7.18 to -3.98
SecondaryMean Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12.

The MENQOL questionnaire was comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assessed four domains of symptoms and functioning: VMS, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicated if they had experienced the symptom (yes/no). If participants selected yes, participants rated how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score were calculated. Each score ranged from 1-8, higher scores indicated greater bother.

Time frame:
From baseline to Week 12
Reported as:
Mean · Scores on scale
Mean Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline to Week 12.
Scores on scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline4.56 ± 1.274.49 ± 1.31
Week 12: Change from baseline-1.41 ± 1.30-0.96 ± 1.11
Statistical analysis
  • Elinzanetant 120 mg vs Placebo - Elinzanetant 120 mg · MMRM · p = < 0.0001 (One-sided. A multiplicity adjustment strategy was defined using the graphical approach, controlling the overall type I error rate at a one-sided alpha level of 0.025 for confirmatory statistical superiority testing.) · Difference in ls-means: -0.42 · 95% CI -0.64 to -0.20
SecondaryMean Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12.

The BDI-II was a 21-item questionnaire assessed the intensity of depressive symptoms over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 mild depression, 20 - 28 indicating moderate and 29 - 63 severe depression (higher score = greater depression).

Time frame:
From baseline to Week 12
Reported as:
Mean · Scores on scale
Mean Beck Depression Inventory (BDI-II) Total Score From Baseline to Week 12.
Scores on scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline6.8 ± 6.56.2 ± 6.7
Week 12: Change from baseline-0.5 ± 7.20.9 ± 6.5
SecondaryMean Change in BDI-II Total Score From Baseline to Week 26.

The BDI-II was a 21-item questionnaire assessing the intensity of depressive symptoms over the past 2 weeks. Each item was a list of four statements arranged in increasing levels of severity about a particular symptom of depression. Items used a 4-point verbal response scale ranging from 0 (not at all) to 3 (extreme form of each symptom); specific response options were tailored to the aspect of depression being measured in each item. A total score ranging from 0 to 63 was calculated with scores of 0-13 indicating mild minimal range, 14 - 19 mild depression, 20 - 28 indicating moderate and 29 - 63 severe depression (higher score = greater depression).

Time frame:
From baseline to Week 26
Reported as:
Mean · Scores on scale
Mean Change in BDI-II Total Score From Baseline to Week 26.
Scores on scaleElinzanetant 120 mgPlacebo - Elinzanetant 120 mg
Baseline6.8 ± 6.56.2 ± 6.7
Week 26: Change from baseline-0.9 ± 6.7-0.6 ± 5.5

Adverse events

Collected over From the start of study medication up to 14 days after the last dose of medication, approximately 28 weeks. Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elinzanetant 120 mg Week 1-120/199 (0%)4/199 (2%)38/199 (19.1%)
Placebo Week 1-120/194 (0%)2/194 (1%)28/194 (14.4%)
Elinzanetant 120 mg Week 13-260/171 (0%)0/171 (0%)6/171 (3.5%)
Placebo - Elinzanetant 120 mg Week 13-260/168 (0%)9/168 (5.4%)9/168 (5.4%)
Elinzanetant 120 mg Week 1-260/367 (0%)13/367 (3.5%)51/367 (13.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventElinzanetant 120 mg Week 1-12Placebo Week 1-12Elinzanetant 120 mg Week 13-26Placebo - Elinzanetant 120 mg Week 13-26Elinzanetant 120 mg Week 1-26
CholelithiasisHepatobiliary disorders0/1991/1940/1712/1682/367
Abdominal painGastrointestinal disorders0/1990/1940/1711/1681/367
Otitis externaInfections and infestations0/1990/1940/1711/1681/367
PyelonephritisInfections and infestations0/1990/1940/1711/1681/367
AccidentInjury, poisoning and procedural complications0/1990/1940/1711/1681/367
Tibia fractureInjury, poisoning and procedural complications0/1990/1940/1711/1681/367
Bunion operationSurgical and medical procedures0/1990/1940/1711/1681/367
MammoplastySurgical and medical procedures0/1990/1940/1711/1681/367
Cholecystitis acuteHepatobiliary disorders0/1991/1940/1710/1680/367
DiverticulitisInfections and infestations1/1990/1940/1710/1681/367
Most frequent other events
Most frequent other events
EventElinzanetant 120 mg Week 1-12Placebo Week 1-12Elinzanetant 120 mg Week 13-26Placebo - Elinzanetant 120 mg Week 13-26Elinzanetant 120 mg Week 1-26
FatigueGeneral disorders14/1993/1940/1711/16815/367
HeadacheNervous system disorders14/1995/1944/1716/16824/367
Depression rating scale score increasedInvestigations12/19911/1941/1712/16814/367
ArthralgiaMusculoskeletal and connective tissue disorders10/19910/1941/1711/16812/367

Baseline characteristics

Full analysis set (FAS) was analyzed. FAS: all randomized subjects were included. Subjects in the full analysis set were analyzed according to the randomized intervention (intention-to-treat).

Age, Continuous
Age, Continuous(years)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Mean54.6 ± 4.954.5 ± 4.954.6 ± 4.9
Sex: Female, Male
Sex: Female, Male(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Female199197396
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
Hispanic or Latino171431
Not Hispanic or Latino180179359
Unknown or Not Reported246
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Elinzanetant 120 mgPlacebo - Elinzanetant 120 mgTotal
American Indian or Alaska Native112
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American383876
White151154305
More than one race303
Unknown or Not Reported437
08

Study locations

99 sites
  • Alabama Clinical Therapeutics | Birmingham, AL
    Birmingham, Alabama 35205, United States
  • Central Research Associates | Birmingham, AL
    Birmingham, Alabama 35205, United States
  • Mesa Obstetricians and Gynecologists | Research Department
    Mesa, Arizona 85206, United States
  • MomDoc Women's Health Research | Scottsdale, AZ
    Scottsdale, Arizona 85251, United States
  • Noble Clinical Research | Tucson, AZ
    Tucson, Arizona 85704, United States
  • Del Sol Research | Women Health studies
    Tucson, Arizona 85715, United States
  • Applied Research Center of Arkansas
    Little Rock, Arkansas 72205, United States
  • Alliance Research Institute | Bell Gardens, CA
    Bell Gardens, California 90201, United States
  • Diagnamics | Encinitas, CA
    Encinitas, California 92024, United States
  • Om Research LLC | Lancaster, CA
    Lancaster, California 93534, United States
  • Northern California Research | Sacramento
    Sacramento, California 95821, United States
  • IntimMedicine | Washington, DC
    Washington D.C., District of Columbia 20036, United States
  • AMR - Fort Myers, FL
    Fort Myers, Florida 33912, United States
  • Suncoast Clinical Research Inc | Pinellas
    Palm Harbor, Florida 34684, United States
  • Physician Care Clinical Research LLC | Sarasota, FL
    Sarasota, Florida 34239, United States
  • Medisense Inc. | Atlanta, GA
    Atlanta, Georgia 30363, United States
  • Paramount Research Solutions | College Park Location
    College Park, Georgia 30349, United States
  • Soapstone Center for Clinical Research, Inc. | Decatur, GA
    Decatur, Georgia 30033-3500, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • M3 Wake Research Atlanta
    Sandy Springs, Georgia 30126, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Investigators Research Group, LLC
    Brownsburg, Indiana 46112, United States
  • The Iowa Clinic - Ankeny
    Ankeny, Iowa 50023, United States
  • Southern Clinical Research Associates | Metairie, LA
    Metairie, Louisiana 70001, United States
  • Continental Clinical Solutions | Towson, MD
    Towson, Maryland 21204, United States
  • Revive Research Institute, Inc. - Women's Health
    Dearborn Heights, Michigan 48127, United States
  • Valley OBGYN
    Saginaw, Michigan 48602, United States
  • Women's Clinic of Lincoln, P.C. | Lincoln, NE
    Lincoln, Nebraska 68510, United States
  • Jubilee Clinical Research Inc | Las Vegas, NV
    Las Vegas, Nevada 89106, United States
  • Affiliated Clinical Research, Inc. | Las Vegas, NV
    Las Vegas, Nevada 89113, United States
  • M3 Wake Research - Clinical Research Center of Nevada
    Las Vegas, Nevada 89123, United States
  • The Center for Womens Health & Wellness, LLC | Lawrenceville, NJ
    Lawrenceville, New Jersey 08648, United States
  • Rutgers Robert Wood Johnson Medical School
    New Brunswick, New Jersey 08901, United States
  • Velocity Clinical Research - Albuquerque
    Albuquerque, New Mexico 87107, United States
  • Bosque Women's Care | Albuquerque, NM
    Albuquerque, New Mexico 87109, United States
  • Circuit Clinical | OB GYN Associates of WNY
    West Seneca, New York 14224, United States
  • OnSite Clinical Solutions - Charlotte
    Charlotte, North Carolina 28277, United States
  • M3 Wake Research | Raleigh, NC
    Raleigh, North Carolina 27612, United States
  • Unified Women's Clinical Research | Lyndhurst Clinical Research, Winston-Salem, NC
    Winston-Salem, North Carolina 27103, United States
  • Axia Women's Health - Anderson Township
    Cincinnati, Ohio 45242, United States
  • Centricity Research - Women's Health - Dublin, OH
    Dublin, Ohio 43016, United States
  • HWC Women's Research Center | Englewood, OH
    Englewood, Ohio 45322, United States
  • Hilltop Obstetrics & Gynecolofy
    Franklin, Ohio 45005, United States
  • Women's Care Research Institute/Marion OBGYN, Inc.
    Marion, Ohio 43302, United States
  • University Hospitals | UH Cleveland Medical Center - MacDonald Clinical Trials Unit
    Mayfield Heights, Ohio 44124, United States
  • Clinical Research Philadelphia | Philadelphia, PA
    Philadelphia, Pennsylvania 19114, United States
  • MUSC Women's Health - Cannon St.
    Charleston, South Carolina 29425, United States
  • Venus Gynecology, LLC | Myrtle Beach, SC
    Myrtle Beach, South Carolina 29572, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Chattanooga Medical Research, LLC. | Chattanooga, TN
    Chattanooga, Tennessee 37404, United States
  • Elligo Health Research | Women Partners in Health PLLC
    Austin, Texas 78705, United States
  • Cedar Health Research, LLC. | DFW-East Clinical Site
    Dallas, Texas 75251, United States
  • Maximos Ob/Gyn
    League City, Texas 77573, United States
  • Northeast Clinical Research of San Antonio, LLC
    San Antonio, Texas 78233, United States
  • Seattle Women's | Seattle, WA
    Seattle, Washington 98105, United States
  • Medical University of Graz | Division of Gynecology and Obstetrics
    Graz, Styria 8036, Austria
  • Medizinische Universitat Innsbruck | Klinik fur Gyn Endokrinologie und Reproduktionsmedizin
    Innsbruck, Tyrol 6020, Austria
  • Kepler Campus IV | Gyn, Gburtshilfe & gyn. Endokrinologie
    Linz, Upper Austria 4020, Austria
  • AKH Wien | Allg. Gynaekologie & gynaekologische Onkologie
    Vienna, 1090, Austria
  • Medizinische Universitat Wien | Universitatsklinik fur Frauenheilkunde Klinische Abteilung fur Gynakologische Endokrinologie
    Vienna, 1090, Austria
  • Gynekologie MEDA s.r.o.
    Brno, 602 00, Czechia
  • G-Centrum Olomouc s.r.o. Dr. Skrivanek
    České Budějovice, 370 01, Czechia
  • GYN-MIKA s.r.o.
    České Budějovice, 370 01, Czechia
  • Gynekologie Cheb s.r.o.
    České Budějovice, 370 01, Czechia
  • MUDr. Stepan s.r.o.
    České Budějovice, 370 01, Czechia
  • GYN-F s.r.o.
    Hradec Králové, 500 03, Czechia
  • Kestr-gyn s.r.o.
    Náchod, 547 01, Czechia
  • PT-MEDICA s.r.o.
    Prachatice, 383 01, Czechia
  • GYNERA
    Prague, 156 00, Czechia
  • Gynekologie Studentsky dum s.r.o.
    Prague, 160 00, Czechia
  • ARETAIEION University Hospital
    Athens, 11528, Greece
  • University General Hospital of Athens "ATTIKON"
    Chaïdári, 12462, Greece
  • University General Hospital of Heraklion - Department of Paediatrics
    Heraklion, 711 10, Greece
  • Univ. General Hospital of Ioannina - Department of Paediatrics, Nephrology Unit
    Ioannina, 45500, Greece
  • University General Hospital of Patras | Univ Obs & Gynae Cli
    Pátrai, 26504, Greece
  • Hippokration General Hospital of Thessaloniki
    Thessaloniki, 54642, Greece
  • General Hospital of Thessaloniki Papageorgiou
    Thessaloniki, 56403, Greece
  • TritonLife Medical Center, XIII.kerulet
    Budapest, 1134, Hungary
  • NAP-MED Egeszsegugyi Szolgaltato Kft
    Debrecen, 4028, Hungary
  • Debreceni Egyetem Klinikai Kozpont
    Debrecen, 4032, Hungary
  • Komaromi Selye Janos Korhaz
    Komárom, 2900, Hungary
  • SZTE ÁOK Szent Györgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Rub-Int Noi Egeszsegcentrum
    Székesfehérvár, 8000, Hungary
  • HaEmek Medical Center | Internal Medicine C Department - Research Unit
    Afula, 1834111, Israel
  • Mayanei HaYeshua Medical Center
    Bnei Brak, 5154475, Israel
  • Hillel Yaffe Medical Center
    Hadera, 3810101, Israel
  • Hadassah Hebrew University Hospital Ein Kerem
    Jerusalem, 9112001, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Health Corporation of Galilee Medical Center
    Nahariya, 2210001, Israel
  • University Hospital Of Ferrara - Ostetricia e Ginecologia
    Ferrara, Emilia-Romagna 44124, Italy
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
  • Ospedale San Raffaele s.r.l. - Ginecologia Ostetricia e Medicina della Riproduzione
    Milan, Lombardy 20132, Italy
  • IRCCS Fondazione Policlinico San Matteo
    Pavia, Lombardy 27100, Italy
  • Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania
    Catania, Sicily 95123, Italy
  • Careggi University Hospital
    Florence, Tuscany 50134, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, Tuscany 56126, Italy
  • Flevoziekenhuis
    Almere Stad, MISSING, Netherlands
  • St. Antonius Ziekenhuis | Utrecht - R&D Interne Geneeskunde
    Nieuwegein, 3435 CM, Netherlands
  • Diakonessenhuis
    Utrecht, 3582 KE, Netherlands
09

References and documents

Publications

  • Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343-54. doi: 10.1001/jama.2024.14618. Online ahead of print. PubMed 39172446 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jul 2023, 22 months.

Results were first posted in Feb 2026, 2 years 6 months after primary completion. A results delay was requested in Jun 2024.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 22 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Sep 13, 2021
StartActual
Aug 27, 2021
Primary completionActual
Jul 25, 2023
CompletionActual
Nov 27, 2023
Results delay requested
Jun 25, 2024
Results first posted
Feb 12, 2026
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05042362
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Aug 27, 2021
Primary completion
Jul 25, 2023
Completion
Nov 27, 2023
Results posted
Feb 12, 2026
Last update
Feb 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elinzanetant

Start the discussion